Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2026, Vol. 40 ›› Issue (6): 63-69.

• Airway Allergic Diseases: From Mechanism to Practice • Previous Articles    

Research progress of Toll-like receptors in allergic rhinitis

TANG Yuchen1, WANG Yan1, TAO Zezhang1,2   

  1. 1. Department of Otorhinolaryngology & Head and Neck Surgery;
    2. Department of Otorhinolaryngology & Head and Neck Surgery Institute, Renmin Hospital of Wuhan University, Wuhan 430000, Hubei, China
  • Published:2026-11-03

PDF (PC)

1

Abstract: Allergic rhinitis is a chronic inflammatory disease characterized by the immune imbalance of Th1/Th2 and Th17/Treg response, and its development is affected by a variety of congenital and acquired factors. As a type of pattern recognition receptors, Toll-like receptors(TLRs)play an important role in the nasal immune defense against external pathogens and in the development of adaptive immune response for the close relation with the maturation and differentiation of T cells. TLR agonists have shown advancements in the immunotherapy of airway inflammatory diseases such as allergic rhinitis and asthma. This article summarizes the research progress on TLRs in the development and treatment of allergic rhinitis.

Key words: Toll-like receptors, Allergic rhinitis, Lipopolysaccharides

CLC Number: 

  • R765.21
[1] Naclerio R, Ansotegui I J, Bousquet J, et al. International expert consensus on the management of allergic rhinitis(AR)aggravated by air pollutants: impact of air pollution on patients with AR: current knowledge and future strategies[J]. World Allergy Organ J, 2020, 13(3): 100106. DOI:10.1016/j.waojou.2020.100106
[2] Wise S K, Damask C, Roland L T, et al. International consensus statement on allergy and rhinology: allergic rhinitis-2023[J]. Int Forum Allergy Rhinol, 2023, 13(4): 293-859. DOI:10.1002/alr.23090
[3] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组、小儿学组. 儿童变应性鼻炎诊断和治疗指南(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(4): 392-404. DOI:10.3760/cma.j.cn115330-20220303-00092
[4] Li D Y, Wu M H. Pattern recognition receptors in health and diseases[J]. Signal Transduct Target Ther, 2021, 6(1): 291. DOI:10.1038/s41392-021-00687-0
[5] Gao W, Xiong Y, Li Q, et al. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics[J]. Front Physiol, 2017, 8: 508. DOI:10.3389/fphys.2017.00508
[6] Suzuki M, Cooksley C, Suzuki T, et al. TLR signals in epithelial cells in the nasal cavity and paranasal sinuses[J]. Front Allergy, 2021, 2: 780425. DOI:10.3389/falgy.2021.780425
[7] Ekman A K, Virtala R, Fransson M, et al. Systemic up-regulation of TLR4 causes lipopolysaccharide-induced augmentation of nasal cytokine release in allergic rhinitis[J]. Int Arch Allergy Immunol, 2012, 159(1): 6-14. DOI:10.1159/000335196
[8] Tengroth L, Millrud C R, Kvarnhammar A M, et al. Functional effects of Toll-like receptor(TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells[J]. PLoS One, 2014, 9(6): e98239. DOI:10.1371/journal.pone.0098239
[9] Renkonen J, Toppila-Salmi S, Joenväärä S, et al. Expression of Toll-like receptors in nasal epithelium in allergic rhinitis[J]. APMIS, 2015, 123(8):716-725. DOI: 10.1111/apm.12408
[10] Cui X Y, Chen X, Yu C J, et al. Increased expression of toll-like receptors 2 and 4 and related cytokines in persistent allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(2): 233-238. DOI:10.1177/0194599814562173
[11] Zhu X W, Cong J N, Yang B, et al. Association analysis of high-mobility group box-1 protein 1(HMGB1)/toll-like receptor(TLR)4 with nasal interleukins in allergic rhinitis patients[J]. Cytokine, 2020, 126: 154880. DOI:10.1016/j.cyto.2019.154880
[12] Wang L H, Zhan M M, Wang J L, et al. Upregulated expression of toll-like receptor 7 in peripheral blood basophils of patients with allergic rhinitis[J]. Am J Rhinol Allergy, 2021, 35(6): 746-760. DOI:10.1177/1945892421993034
[13] Bergougnan C, Dittlein D C, Hümmer E, et al. Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donors[J]. World Allergy Organ J, 2020, 13(3): 100109. DOI:10.1016/j.waojou.2020.100109
[14] Clarke T B, Francella N, Huegel A, et al. Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium[J]. Cell Host Microbe, 2011, 9(5): 404-414. DOI:10.1016/j.chom.2011.04.012
[15] Ohkuni T, Kojima T, Ogasawara N, et al. Poly(I: C)reduces expression of JAM-A and induces secretion of IL-8 and TNF-α via distinct NF-κB pathways in human nasal epithelial cells[J]. Toxicol Appl Pharmacol, 2011, 250(1): 29-38. DOI:10.1016/j.taap.2010.09.023
[16] Ryu J H, Yoo J Y, Kim M J, et al. Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways[J]. J Allergy Clin Immunol, 2013, 131(2): 549-561. DOI:10.1016/j.jaci.2012.07.050
[17] Kim G, Hong M, Kashif A, et al. Der f 38 is a novel TLR4-binding allergen related to allergy pathogenesis from Dermatophagoides farinae[J]. Int J Mol Sci, 2021, 22(16): 8440. DOI:10.3390/ijms22168440
[18] Ebrahim Soltani Z, Badripour A, Haddadi NS, et al. Allergic rhinitis in BALB/c mice is associated with behavioral and hippocampus changes and neuroinflammation via the TLR4/NF-κB signaling pathway[J]. Int Immunopharmacol, 2022, 108: 108725. DOI:10.1016/j.intimp.2022.108725
[19] Li D Q, Zhang L L, Pflugfelder S C, et al. Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4-dependent thymic stromal lymphopoietin/OX40 ligand/OX40 signaling pathways[J]. J Allergy Clin Immunol, 2011, 128(6): 1318-1325.e2. DOI:10.1016/j.jaci.2011.06.041
[20] Zheng R, Chen F H, Gao W X, et al. The TH2-polarizing function of atopic interleukin 17 receptor B-positive dendritic cells up-regulated by lipopolysaccharide[J]. Ann Allergy Asthma Immunol, 2017, 118(4): 474-482.e1. DOI:10.1016/j.anai.2016.12.011
[21] Zheng R, Chen Y, Shi J B, et al. Combinatorial IL-17RB, ST2, and TSLPR signaling in dendritic cells of patients with allergic rhinitis[J]. Front Cell Dev Biol, 2020, 8: 207. DOI:10.3389/fcell.2020.00207
[22] Deifl S, Kitzmüller C, Steinberger P, et al. Differential activation of dendritic cells by toll-like receptors causes diverse differentiation of na ve CD4+ T cells from allergic patients[J]. Allergy, 2014, 69(12): 1602-1609. DOI:10.1111/all.12501
[23] Eisenbarth S C, Piggott D A, Huleatt J W, et al. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen[J]. J Exp Med, 2002, 196(12): 1645-1651. DOI:10.1084/jem.20021340
[24] Volpi C, Fallarino F, Pallotta M T, et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway[J]. Nat Commun, 2013, 4: 1852. DOI:10.1038/ncomms2874
[25] Thio C L, Lai A C, Chi P Y, et al. Toll-like receptor 9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity[J]. J Allergy Clin Immunol, 2019, 144(3): 682-697.e9. DOI:10.1016/j.jaci.2019.03.008
[26] Crellin N K, Garcia R V, Hadisfar O, et al. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells[J]. J Immunol, 2005, 175(12): 8051-8059. DOI:10.4049/jimmunol.175.12.8051
[27] Round J L, Mazmanian S K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota[J]. Proc Natl Acad Sci U S A, 2010, 107(27): 12204-12209. DOI:10.1073/pnas.0909122107
[28] Zhao M, Zeng H T, Yang G, et al. Toll-like receptor signal is required in maintenance of immune suppressive capacity of regulatory T cells[J]. Immunol Lett, 2019, 210: 47-54. DOI:10.1016/j.imlet.2019.04.005
[29] Rouadi P W, Idriss S A, Naclerio R M, et al. Immunopathological features of air pollution and its impact on inflammatory airway diseases(IAD)[J]. World Allergy Organ J, 2020, 13(10): 100467. DOI:10.1016/j.waojou.2020.100467
[30] Fonceca A M, Zosky G R, Bozanich E M, et al. Accumulation mode particles and LPS exposure induce TLR-4 dependent and independent inflammatory responses in the lung[J]. Respir Res, 2018, 19(1): 15. DOI:10.1186/s12931-017-0701-z
[31] Ege M J, Bieli C, Frei R, et al. Prenatal farm exposure is related to the expression of receptors of the innate immunity and to atopic sensitization in school-age children[J]. J Allergy Clin Immunol, 2006, 117(4): 817-823. DOI:10.1016/j.jaci.2005.12.1307
[32] Stein M M, Hrusch C L, Gozdz J, et al. Innate immunity and asthma risk in Amish and Hutterite farm children[J]. N Engl J Med, 2016, 375(5): 411-421. DOI:10.1056/NEJMoa1508749
[33] Yu N, Weng Y M, Liu W, et al. TLRs induce Th1/Th2 responses by affecting the secretion of CCL2 at the maternal-foetal interface[J]. Int Immunopharmacol, 2021, 100: 108070. DOI:10.1016/j.intimp.2021.108070
[34] Yu J Y, Liu X Q, Li Y L, et al. Maternal exposure to farming environment protects offspring against allergic diseases by modulating the neonatal TLR-Tregs-Th axis[J]. Clin Transl Allergy, 2018, 8: 34. DOI:10.1186/s13601-018-0220-0
[35] Golebski K, van Tongeren J, van Egmond D, et al. Specific induction of TSLP by the viral RNA analogue poly(I: C)in primary epithelial cells derived from nasal polyps[J]. PLoS One, 2016, 11(4): e0152808. DOI:10.1371/journal.pone.0152808
[36] Suzuki M, Ramezanpour M, Cooksley C, et al. Sirtuin-1 controls poly(I: C)-dependent matrix metalloproteinase 9 activation in primary human nasal epithelial cells[J]. Am J Respir Cell Mol Biol, 2018, 59(4): 500-510. DOI:10.1165/rcmb.2017-0415OC
[37] Ellis A K, Tsitoura D C, Quint D, et al. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial[J]. Clin Exp Allergy, 2017, 47(9): 1193-1203. DOI:10.1111/cea.12974
[38] Psallidas I, Backer V, Kuna P, et al. A phase 2a, double-blind, placebo-controlled randomized trial of inhaled TLR9 agonist AZD1419 in asthma[J]. Am J Respir Crit Care Med, 2021, 203(3): 296-306. DOI:10.1164/rccm.202001-0133OC
[39] Jensen-Jarolim E, Roth-Walter F, Jordakieva G, et al. Allergens and Adjuvants in Allergen Immunotherapy for Immune Activation, Tolerance, and Resilience[J]. J Allergy Clin Immunol Pract, 2021, 9(5): 1780-1789. DOI:10.1016/j.jaip.2020.12.008
[40] Starchenka S, Heath M D, Lineberry A, et al. Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy[J]. World Allergy Organ J, 2019, 12(11): 100087. DOI:10.1016/j.waojou.2019.100087
[41] Starchenka S, Oluwayi K, Heath M, et al. Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy[J]. Clin Exp Allergy, 2024, 54(2): 130-142. DOI:10.1111/cea.14432
[42] Worm M, Higenbottam T, Pfaar O, et al. Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy[J]. Allergy, 2018, 73(9): 1812-1822. DOI:10.1111/all.13478
[43] Florido-López J F, Andreu-Balaguer C, Escudero C, et al. Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: a retrospective, controlled real-world study[J]. World Allergy Organ J, 2020, 13(12): 100487. DOI:10.1016/j.waojou.2020.100487
[44] de Kam P J, Zielen S, Bernstein J A, et al. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy[J]. Allergy, 2023, 78(10): 2756-2766. DOI:10.1111/all.15788
[45] Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial[J]. Clin Exp Allergy, 2009, 39(4): 562-570. DOI:10.1111/j.1365-2222.2008.03191.x
[46] Ellis A K, Tsitoura D C, Quint D, et al. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial[J]. Clin Exp Allergy, 2017, 47(9): 1193-1203. DOI:10.1111/cea.12974
[47] Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study[J]. Clin Exp Allergy, 2011, 41(9): 1305-1312. DOI:10.1111/j.1365-2222.2011.03783.x
[48] Lin Y J, Papp G, Miskey C, et al. The flagellin: allergen fusion protein rFlaA: Betv1 induces a MyD88- and MAPK-dependent activation of glucose metabolism in macrophages[J]. Cells, 2021, 10(10): 2614. DOI:10.3390/cells10102614
[49] Mo J H, Park S W, Rhee C S, et al. Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis[J]. Am J Rhinol, 2006, 20(2): 212-218
[50] 林小燕, 李静, 马志祺, 等. 益生菌治疗变应性鼻炎的临床疗效及抗变态反应作用Meta分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 70-80. DOI:10.6040/j.issn.1673-3770.0.2020.374
[51] Meng Q, Li P, Li Y, et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa[J]. Rhinology, 2019, 57(6): 451-459. DOI:10.4193/Rhin19.161
[52] Yu J I, Kim J H, Nam K E, et al. Pneumococcal Δpep27 immunization attenuates TLRs and NLRP3 expression and relieves murine ovalbumin-induced allergic rhinitis[J]. J Microbiol Biotechnol, 2022, 32(6): 709-717. DOI:10.4014/jmb.2203.03006
[1] HU Huixuan, PAN Li, LIAO Wenxi, FENG Yan. Efficacy and compliance of Artemisia annua pollen allergen sublingual drops in the treatment of monosensitized and polysensitized allergic rhinitis patients [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(6): 22-29.
[2] SHENG Xinyue, ZHANG Biaoxin, LIU Yehai, WU Feihu, CAI En, XU Jing. Efficacy observation of acupoint massage combined with auricular acupressure in the treatment of moderate to severe persistent allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(6): 40-45.
[3] LIU Danfeng, PAN Qingchun, FENG Xuefei, LI Haoyi, REN Jian, LI Daibo. Development and validation of a nomogram for predicting asthma comorbidity in elderly patients with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(6): 54-62.
[4] LYU Qian, TANG Yuan, GU Zijun, SHI Sailei, LIU Ping, WAN Wenjin. Current status of benefit finding among patients with allergic rhinitis and its influence factors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 21-28.
[5] GU Min, LU Meiping. Advances in the application of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 106-111.
[6] QIN Nana, LI Yufen, SUN Yuhao, WEI Jian, LI Qin. Effect of interleukin-13 receptor-α2 on nasal mucosal remodeling in rats with allergic rhinitis by TGF-β1/Smad signaling pathway [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 71-77.
[7] DU Kangli, ZHENG Zhenyu, XU Zhanjiang, ZHANG Yu, CHEN Lu, LU Mengyao. Construction and validation of risk prediction model for nasal septal deviation complicated with chronic sinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 78-86.
[8] XIONG Qin, ZHANG Yan, WU Rina, LI Feng, TANG Lixing. Application of intranasal corticosteroids in pediatrics [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 160-167.
[9] XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33.
[10] HUANG Huan, HUA Hongli, DENG Yuqin, JIANG Chengyang, WANG Yuwei, YANG Xinghai. Correlation of allergic rhinitis, tonsil adenoid hypertrophy, and sinusitis in children and analysis of its clinical guiding value [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 34-41.
[11] LIU Yijun, GU Yue, GUAN Dayu, YANG Yucheng, SHEN Yang. The long-term clinical efficacy and safety of vidian neurectomy in refractory allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 42-48.
[12] ZHANG Ting, WANG Meilan, GAO Yingqin. Research progress of IL-35 in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 139-147.
[13] ZHANG Zhuping, PENG Zican, XIAO Zhenlong, LI Cheng, YU Di, WANG Xinglong, CHEN Wei, Guo Bei. The value of a novel nasal secretion eosinophil cationic protein-myeloperoxidase test paper assay in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 129-134.
[14] LIU Chang, YANG Jingpu, GAO Yu, WANG Wenjia. Analysis of allergen detection results in children with allergic rhinitis in the Changchun area [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 51-58.
[15] ZHOU Heqing, SHEN Qi. Research progress on biomarkers of traditional Chinese medicine in the treatment of allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 168-176.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd